TG Therapeutics Inc (TGTX)
39.82
+2.07
(+5.48%)
USD |
NASDAQ |
Apr 02, 16:00
38.50
-1.32
(-3.31%)
After-Hours: 07:37
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 6.255B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 175.8% |
| Valuation | |
| PE Ratio | 284.43 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 18.96 |
| Price to Book Value | 28.13 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 1.099 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 93.19% |
Profile
Edit
| TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries. |
| URL | https://www.tgtherapeutics.com |
| Investor Relations URL | https://ir.tgtherapeutics.com/ |
| HQ State/Province | North Carolina |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | May. 01, 2025 (est.) |
| Last Earnings Release | Mar. 03, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
Edit
| TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries. |
| URL | https://www.tgtherapeutics.com |
| Investor Relations URL | https://ir.tgtherapeutics.com/ |
| HQ State/Province | North Carolina |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | May. 01, 2025 (est.) |
| Last Earnings Release | Mar. 03, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |